Monogram Announces 2008 Third Quarter Financi... (

Monogram Announces 2008 Third Quarter Financial Results

Date:10/27/2008

- Conference call today at 4:30 p.m. ET -

SOUTH SAN FRANCISCO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today reported financial results for the quarter ended September 30, 2008.

The Company had revenues of $16.1 million for the third quarter of 2008, 55% higher than $10.4 million in the third quarter of 2007. This growth was driven by revenue from Trofile(TM) for selecting HIV patients to be treated with Selzentry(TM), Pfizer's CCR5 antagonist, and by revenue from use of Monogram's PhenoSense HIV(TM) resistance test and Trofile in a phase III trial by a pharmaceutical company customer.

Revenue for the nine months ended September 30, 2008 was $47.1 million, an increase of 60% over $29.5 million in the first nine months of 2007.

In addition to the reported revenue for the quarter, Monogram recorded as deferred revenue, the sale of Trofile assays to Pfizer for patient testing outside of the U.S. and for use in clinical trials. These deferred revenues were $1.6 million and $3.6 million for the three and nine months ended September 30, 2008, respectively. This revenue was recorded as deferred revenue due to the accounting for the Company's collaboration with Pfizer. Had these sales not been accounted for as deferred revenue, total revenue on a Non-GAAP basis, for the three and nine months ended September 30, 2008 would have been $17.7 million and $50.7 million, respectively.

Monogram has performed over 10,000 Trofile tests to date for U.S. patients and revenue from Trofile in the quarter ended September 30, 2008 was $4.8 million.

"Revenues were again at a record level in the third quarter," said Alfred Merriweather, Monogram's Chief Financial Off
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
2. Monogram Biosciences to Present at the ThinkEquity Partners Fifth Annual Growth Conference
3. Monogram Biosciences to Present at the JMP Securities Healthcare Conference
4. Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call
5. Monogram Announces Third Quarter 2007 Financial Results
6. Monogram Biosciences to Present at the Piper Jaffray 19th Annual Healthcare Conference
7. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
8. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
9. Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
10. Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
11. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program

Post Your Comments:

Monogram Announces 2008 Third Quarter Financi...( - Conference call to...)